Idorsia-led Portfolio

Compound Mechanism of action Target indication Status More Information
         

QUVIVIQ™   (daridorexant)

Dual orexin receptor antagonist

Insomnia

Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, and France; 
approved throughout the EU

Investor webcast

TRYVIO™ (aprocitentan) 

Dual endothelin receptor antagonist

Systemic hypertension in combination with other antihypertensive drugs Approved in the US, product availability planned for Q4 2024

Investor webcast

JERAYGO™ (aprocitentan) 

Dual endothelin receptor antagonist

Resistant hypertension in combination with other antihypertensive drugs Positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) received in April 2024 - European Commission decision expected in approx. 2 months Investor webcast

Lucerastat

Glucosylceramide synthase inhibitor

Fabry disease

Phase 3 primary endpoint not met, open-label extension study ongoing
Phase 3 focused on renal function in preparation

 

ACT-1004-1239

ACKR3/CXCR7 antagonist

Demyelinating diseases including multiple sclerosis

Phase 2 in preparation

 

Sinbaglustat

GBA2/GCS inhibitor

Rare lysosomal storage disorders

Phase 1 complete

 

ACT-777991

CXCR3 antagonist

Recent-onset Type 1 diabetes

Phase 1 complete

 

IDOR-1117-2520

Undisclosed

Immune-mediated disorders

Phase 1

 
IDOR-1134-2831

Synthetic glycan vaccine

Clostridium difficile infection

Phase 1 initiating

 

Partner-led Portfolio

Compound Mechanism of action              Target indication

Partner: Terms

Status
         

Daridorexant                         

Dual orexin receptor 
antagonist                             

Insomnia  

Nxera Pharma: license to develop and commercialize 
for Asia-Pacific region (excluding China) 

NDA submitted in Japan

Daridorexant

Dual orexin receptor antagonist

Insomnia

Simcere: license to develop and commercialize
for the Greater China region

Phase 3 ongoing

Selatogrel

P2Y12 inhibitor              

Suspected acute myocardial infarction

Viatris: worldwide development and commercialization rights

Phase 3 “SOS-AMI” program ongoing

Cenerimod

S1P1 receptor modulator   

Systemic lupus erythematosus    

Viatris: worldwide development and commercialization rights (excluding Japan, South Korea, and certain countries in the Asia-Pacific region)

Phase 3 “OPUS” program ongoing

Daridorexant

Dual orexin receptor antagonist

Posttraumatic stress
disorder (PTSD)

US Department of Defense (DOD):  Idorsia supports a clinical study sponsored
by the US DOD to develop new therapies to treat PTSD

Phase 2
ACT-709478/
NBI-827104
T-type calcium channel blocker Epileptic
encephalopathy with
continuous spike-and-wave during sleep (CSCW)

Neurocrine Biosciences: global license to develop and commercialize

Phase 2 OLE study ongoing
ACT-1002-4391 EP2 / EP4 receptor antagonist Immuno-oncology Owkin: global license to develop and 
commercialize
Phase 1 in preparation